Juliana C.N. ChanPongamorn BunnagSiew P. ChanIris T.I. TanShih Tzer TsaiLing GaoWolfgang LandgrafCheng Hsin General HospitalUniversity of the Philippines ManilaPrince of Wales Hospital Hong KongFaculty of Medicine, Ramathibodi Hospital, Mahidol UniversityUniversity of Malaya Medical CentreAnalysta Inc.Sanofi2019-08-232019-08-232018-01-01Diabetes Research and Clinical Practice. Vol.135, (2018), 199-20518728227016882272-s2.0-85037357363https://repository.li.mahidol.ac.th/handle/123456789/45341© 2017 Aims To compare outcomes between Asian and non-Asian patients with type 2 diabetes (T2D) inadequately controlled on oral antidiabetic drugs (OADs) initiating insulin glargine 100 units (U)/mL (Gla-100) in randomised controlled clinical trials. Methods Post hoc analysis of patient-level data (Asian n = 235; non-Asian n = 3351) from 16 trials. Results At baseline, Asian patients were younger with lower body mass index (BMI), fasting C-peptide, and fasting plasma glucose (FPG) than non-Asian patients (all P <.001). Asian patients had a higher mean glycosylated haemoglobin (HbA1c) at Week 24 and less reduction in HbA1c from baseline (7.4% vs. 7.2%; −1.3% vs. −1.6%, respectively; P =.0001), and were less likely to achieve HbA1c <7.0% (40% vs. 47%; P =.002) than non-Asian patients. Reductions in FPG and rates of hypoglycaemia were similar between Asian and non-Asian patients. Asian patients had less weight gain than non-Asian patients (+1.3 vs. +1.9 kg, respectively, P =.013). Conclusions In our post hoc meta-analysis, Gla-100 effectively lowers HbA1c and FPG in Asian patients with T2D uncontrolled on OADs with similar incidence of hypoglycaemia and less absolute weight gain compared with non-Asian patients. At a similar FPG reduction, fewer Asian patients achieved HbA1c target <7.0%, suggesting that prandial glucose needs to be addressed.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyMedicineArticleSCOPUS10.1016/j.diabres.2017.11.025